飞秒激光辅助白内障手术的成本效用与信息价值分析
本研究为FEMCAT随机临床试验的预设次要经济学分析,在法国5家大学医院中心比较飞秒激光辅助白内障手术(FLACS)与超声乳化白内障手术(PCS)的12个月成本效用。FLACS平均费用高于PCS,QALYs差异为-0.004(95%CI,-0.028至0.021),ICER为-€136 476/QALY,在€30 000/QALY阈值下FLACS具有成本效用的概率为15.7%。作者认为FLACS的ICER不在常被引用的$50 000至$100 000/QALY成本有效范围内,需要进一步研发以提高其效果并降低价格。
要点
- FLACS平均手术费用€1124.0,PCS为€565.5;12个月总平均费用FLACS €7085,PCS €6502。
- FLACS平均QALYs为0.788,PCS为0.792;QALYs差异-0.004(95%CI,-0.028至0.021)。
- ICER为-€136 476/QALY,€30 000/QALY阈值下FLACS成本效用概率为15.7%。
核心结论
- FLACS与PCS比较的ICER不在常被引用的每QALY $50 000至$100 000成本有效范围内。
- 作者认为需要针对FLACS开展进一步研发以提高其效果并降低其价格。
研究设计与样本
- 本研究为多中心随机临床试验,平行组比较FLACS与PCS,所有FLACS手术均使用CATALYS precision系统。
- 参与者在法国5家大学医院中心的门诊手术场所招募并接受治疗,纳入连续、年龄22岁及以上、有书面知情同意、适合单眼或双眼白内障手术的患者。
- 数据收集时间为2013年10月至2018年10月,数据分析时间为2020年1月至2022年6月。
- 共随机870例患者,其中440例随机接受FLACS、430例接受PCS;543例(62.4%)为女性,手术时平均(SD)年龄为72.3(8.6)岁;双眼手术率为63.3%(551/870)。
主要发现
- 白内障手术平均(SD)费用FLACS为€1124.0(€162.2;US $1235),PCS为€565.5(€61.4;US $621)。
- 12个月总平均(SD)照护费用FLACS组为€7085(€6700;US $7787),PCS组为€6502(€7323;US $7146)。
- FLACS平均(SD)获得0.788(0.009)QALYs,PCS获得0.792(0.009)QALYs。
- 平均费用差异为€545.9(95%CI,-434.1至1525.8;US $600),QALYs差异为-0.004(95%CI,-0.028至0.021)。
- ICER为-€136 476(US $150 000)/QALY;在€30 000(US $32 973)/QALY成本效用阈值下,FLACS相对于PCS的成本效用概率为15.7%;该阈值下完全信息期望价值为€246 139 079(US $270 530 231)。
关键数值与推荐
- 效用通过健康效用指数(Health Utility Index)问卷测量。
- 白内障手术费用通过微观成本法估计,所有住院和门诊费用均从法国国家健康数据系统收集。
- 费用差异为€545.9(95%CI,-434.1至1525.8;US $600),QALYs差异为-0.004(95%CI,-0.028至0.021)。
- ICER为-€136 476(US $150 000)/QALY;€30 000(US $32 973)/QALY阈值下FLACS的成本效用概率为15.7%;该阈值下完全信息期望价值为€246 139 079(US $270 530 231)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The efficacy and safety of femtosecond laser-assisted cataract surgery is well documented. An important requirement for decision makers is the evaluation of the cost-effectiveness of femtosecond laser-assisted cataract surgery (FLACS) over a sufficiently long horizon. Evaluating the cost-effectiveness of this treatment was a preplanned secondary objective of the Economic Evaluation of Femtosecond Laser Assisted Cataract Surgery (FEMCAT) trial. OBJECTIVE: To estimate the cost utility of FLACS compared with phacoemulsification cataract surgery (PCS) on a 12-month time horizon. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial compared FLACS with PCS in parallel groups. All FLACS procedures were performed using the CATALYS precision system. Participants were recruited and treated in ambulatory surgery settings in 5 university-hospital centers in France. All consecutive patients eligible for a unilateral or bilateral cataract surgery 22 years or older with written informed consent were included. Data were collected from October 2013 to October 2018, and data were analyzed from January 2020 to June 2022. INTERVENTIONS: FLACS or PCS. MAIN OUTCOMES AND MEASURES: Utility was measured through the Health Utility Index questionnaire. Costs of cataract surgery were estimated by microcosting. All inpatient and outpatient costs were collected from the French National Health Data System. RESULTS: Of 870 randomized patients, 543 (62.4%) were female, and the mean (SD) age at surgery was 72.3 (8.6) years. A total of 440 patients were randomized to receive FLACS and 430 to receive PCS; the rate of bilateral surgery was 63.3% (551 of 870). The mean (SD) costs of cataract surgery were €1124.0 (€162.2; US $1235) for FLACS and €565.5 (€61.4; US $621) for PCS. The total mean (SD) cost of care at 12 months was €7085 (€6700; US $7787) in participants treated with FLACS and €6502 (€7323; US $7146) in participants treated with PCS. FLACS yielded a mean (SD) of 0.788 (0.009) quality-adjusted life-years (QALYs), and PCS yielded 0.792 (0.009) QALYs. The difference in mean costs was €545.9 (95% CI, -434.1 to 1525.8; US $600), and the difference in QALYs was -0.004 (95% CI, -0.028 to 0.021). The incremental cost-effectiveness ratio (ICER) was -€136 476 (US $150 000) per QALY. The cost-effectiveness probability of FLACS compared with PCS was 15.7% for a cost-effectiveness threshold of €30 000 (US $32 973) per QALY. At this threshold, the expected value of perfect information was €246 139 079 (US $270 530 231). CONCLUSIONS AND RELEVANCE: The ICER of FLACS compared with PCS was not within the $50 000 to $100 000 per QALY range frequently cited as cost-effective. Additional research and development on FLACS is needed to improve its effectiveness and lower its price. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01982006.
引用
- Bénard A, Sitta R, Brezin AP, et al. Cost Utility and Value of Information Analysis of Femtosecond Laser-Assisted Cataract Surgery. JAMA Ophthalmol. 2023. PMID: 37200037. doi:10.1001/jamaophthalmol.2023.1716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。